Antibody Breaks Leukemia’s Hold, Providing New Therapeutic Approach

In mouse models and patient cells, anti-CD98 antibody disrupts interactions between leukemia cells and surrounding blood vessels, inhibiting cancer’s growth —

Acute myeloid leukemia (AML) is an aggressive cancer known for drug resistance and relapse. In an effort to uncover new treatment strategies, researchers at University of California San Diego School of Medicine and Moores Cancer Center discovered that a cell surface molecule known as CD98 promotes AML. … Read the Full Story from the UC San Diego Newsroom


Dr. Mark Ginsberg

Dr. Mark Ginsberg

Department of Medicine Professor Mark H. Ginsberg, MD, co-directed the study with Tannishtha Reya, PhD, professor of pharmacology.

Dr. Ginsberg is Professor of Medicine in the Division of Rheumatology, Allergy & Immunology at UC San Diego School of Medicine and Moores Cancer Center.

Read the study report

Visit Dr. Ginsberg’s Lab Website

Cancer-associated Mutations are Common in Patients with Unexplained Low Blood Counts

November 4, 2015

Researchers use genetic tools to propose a new diagnostic category —

Patients with unexplained low blood counts and abnormally mutated cells who do not fit the diagnostic criteria for recognized blood cancers should be described as having clonal cytopenias of undetermined significance (CCUS), suggest University of California, San Diego School of Medicine researchers in a recent paper published in the journal Blood. The researchers found the condition surprisingly common in older patients with low blood counts. … Read the full story from the UC San Diego Newsroom


Dr. Rafael Bejar

Dr. Rafael Bejar

The senior author of the study is Rafael Bejar, MD, PhD, Assistant Professor of Medicine in the Division of Bone Marrow Transplantation.

Read Article Abstract

Dr. Bejar was one of 41 UC San Diego Health physicians named on the list of San Diego’s Top Doctors for 2015. The annual list is compiled by the San Diego County Medical Society and San Diego Magazine.